RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment
Company Name Change:
ARMGO Pharma has rebranded as RyCarma Therapeutics, reflecting its focus on ryanodine receptor (RyR) biology and the therapeutic potential of Rycals, a novel class of small molecule drugs14.
New Leadership:
RyCarma has introduced new leadership members, including Adam Rosenberg as CEO, Jonathan Alspaugh as President & Chief Strategy Officer, and Sanjay Jalota as Senior Vice President of Regulatory, backed by a strong investor syndicate1.
Lead Candidate:
The company is advancing its lead candidate ARM210, which targets leaky RyRs to correct calcium channel dysfunction in both cardiac and skeletal muscle cells, initially focusing on heart failure and ryanodine receptor 1-related myopathies14.
Heart Failure Program:
RyCarma’s new program focuses on developing ARM210 for heart failure with reduced ejection fraction, aiming to address the underlying driver of disease progression and strengthen both cardiac and skeletal muscle cells15.
Foundational Research:
The company builds on the pioneering work of its founder Dr. Andrew Marks, who cloned the RyR and described its structure at atomic resolution, highlighting the central role of RyRs in human biology14.
Exclusive License:
RyCarma holds an exclusive license from Columbia University for its RyR technology based on Dr. Marks’ research14.
Clinical Progress:
ARM210 has shown improvement in fatigue and proximal muscle strength in a Phase 1b trial for RYR1-RM and is well-tolerated with no dose-dependent safety signals or serious adverse events1.
Sources:
1. https://www.biospace.com/press-releases/rycarma-therapeutics-announces-new-leadership-and-company-name-introduces-program-in-heart-failure